about
Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseasesSilencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy.Cartilage intermediate layer protein 2 (CILP-2) is expressed in articular and meniscal cartilage and down-regulated in experimental osteoarthritis.Changes in the chondrocyte and extracellular matrix proteome during post-natal mouse cartilage development.Long-Term Overexpression of Hsp70 Does Not Protect against Cardiac Dysfunction and Adverse Remodeling in a MURC Transgenic Mouse Model with Chronic Heart Failure and Atrial FibrillationTherapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart functionInhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure OverloadThe bone morphogenetic protein axis is a positive regulator of skeletal muscle mass.Therapeutic potential of targeting microRNAs to regulate cardiac fibrosis: miR-433 a new fibrotic player.A microRNA guide for clinicians and basic scientists: background and experimental techniques.Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways.The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy.MicroRNAs differentially regulated in cardiac and skeletal muscle in health and disease: potential drug targets?Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets.miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart.From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart FailureHSP70: therapeutic potential in acute and chronic cardiac disease settings.Molecular Aspects of Exercise-induced Cardiac Remodeling.Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice.β-Adrenergic Stimulation Induces Histone Deacetylase 5 (HDAC5) Nuclear Accumulation in Cardiomyocytes by B55α-PP2A-Mediated Dephosphorylation.Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction.Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs.A microarray approach for comparative expression profiling of the discrete maturation zones of mouse growth plate cartilage.The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection.Enhanced phosphoinositide 3-kinase(p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes.PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA.The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice.Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy
P50
Q28583018-AF8650C0-0F1E-4D48-BE2B-B4A227E5358BQ35108974-4086BE13-FCBB-4CC1-9BF3-4D0A46D241FAQ35424110-B6F75944-4C09-44D0-BD53-5ED1CB7F5CC7Q35722323-3B364BDB-E947-44E3-960F-5C276B7386A7Q35867492-87842608-83CF-4D81-AC6D-6EA950011019Q36378477-449437F8-F1A0-4B18-933B-8852E10795C0Q36634367-826AE8E0-61EF-4778-8156-06DDB861BA09Q37267961-77B1FB65-BCAD-4B0E-A68C-1D59FEB5F5CAQ37583782-D4396758-18B2-4FA8-B6DE-42052D54FC13Q37966411-FC79D2ED-2C21-4FE2-9547-F69A4045CD7AQ38181816-3A60892A-E556-45A4-B2CE-82C48CCA151BQ38182139-E14DFF67-5AD1-4E18-87ED-F4A53ED40B37Q38239202-664BEC13-B783-4160-9BEA-81660DC2AD25Q38364630-5725A92E-5B86-44D5-B989-205A7B05B08FQ38591803-16AC049A-AB9C-4FC7-A308-6F44AF863E3BQ38780801-84DBC482-F68E-4DB5-9A2B-442450414518Q38795296-D35030FE-BA62-4F34-BD36-291CA26162F4Q38969269-C2369CCB-140E-42F0-BB87-EE3C246B76A4Q40640594-6B69E454-008B-43E2-9EC7-C4BBD337C2B7Q41165926-3A66A4A1-1537-476C-8ABE-C4F97B74565BQ45879808-153DDD0D-D8FA-4434-B2D1-E0EA0C5160B4Q48211539-E6A79FBF-8E03-4844-97BD-E827F70A0CC4Q51960849-033B54DE-60B7-4E1C-8789-23B531A90173Q54139767-5341563C-5251-40FC-9DA5-71CE6804F315Q54481875-65003DD9-0677-4846-A061-86EBB943412CQ54686097-A8D65FCB-EFC9-477B-8A33-A5C028BB723FQ55069411-92244404-05BD-4B17-85AB-E7D0BBE208E0Q87634570-D6147090-0A4F-4914-BB5B-BFC3A8A29910
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bianca C Bernardo
@nl
Bianca C Bernardo
@sl
Bianca C. Bernardo
@en
Bianca C. Bernardo
@es
type
label
Bianca C Bernardo
@nl
Bianca C Bernardo
@sl
Bianca C. Bernardo
@en
Bianca C. Bernardo
@es
prefLabel
Bianca C Bernardo
@nl
Bianca C Bernardo
@sl
Bianca C. Bernardo
@en
Bianca C. Bernardo
@es
P106
P1153
24172961400
P21
P31
P496
0000-0002-4534-0549